Miricorilant + Fluvoxamine
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Antipsychotic Induced Weight Gain
Conditions
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Trial Timeline
Jan 24, 2023 → Feb 23, 2023
NCT ID
NCT05712265About Miricorilant + Fluvoxamine
Miricorilant + Fluvoxamine is a phase 1 stage product being developed by Corcept Therapeutics for Antipsychotic Induced Weight Gain. The current trial status is completed. This product is registered under clinical trial identifier NCT05712265. Target conditions include Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH).
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05712265 | Phase 1 | Completed |
Competing Products
3 competing products in Antipsychotic Induced Weight Gain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miricorlilant + Miricorlilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Miricorilant + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| Olanzapine + CORT118335 + Placebo | Corcept Therapeutics | Phase 1 | 28 |